[ULTRASTRUCTURE OF PARACOCCIDIOIDES BRASILIENSIS IN CULTURES OF THE YEAST-LIKE PHASE].

L. Carbonell,L. Pollak

Mycopathologia et Mycologia Applicata

Abstract:

What problem does this paper attempt to address?

New insight on the enteric cholinergic innervation of the pig colon by central and peripheral nervous systems: reduction by repeated loperamide administration

Pu-Qing Yuan,Tao Li,Mulugeta Million,Muriel Larauche,Karim Atmani,Jean-Pierre Bellier,Yvette Taché

DOI: https://doi.org/10.3389/fnins.2023.1204233

IF: 4.3

2023-08-16

Frontiers in Neuroscience

Abstract:Introduction: The central and peripheral nervous systems provide cholinergic innervation in the colon. The ability to assess their neuroanatomical distinctions is still a challenge. The pig is regarded as a relevant translational model due to the close similarity of its enteric nervous system (ENS) with that of human. Opioid-induced constipation is one of the most common side effects of opioid therapy. Methods: We developed an approach to differentiate the central and peripheral cholinergic innervation of the pig colon using double immunolabeling with a novel mouse anti-human peripheral type of choline acetyltransferase (hpChAT) antibody combined with a rabbit anti-common type of ChAT (cChAT) antibody, a reliable marker of cholinergic neurons in the central nervous system. We examined their spatial configurations in 3D images of the ENS generated from CLARITY-cleared colonic segments. The density was quantitated computationally using Imaris 9.7. We assessed changes in the distal colon induced by daily oral treatment for 4 weeks with the μ opioid receptor agonist, loperamide (0.4 or 3 mg/kg). Results: The double labeling showed strong cChAT immunoreactive (ir) fibers in the cervical vagus nerve and neuronal somata and fibers in the ventral horn of the sacral (S2) cord while hpChAT immunoreactivity was visualized only in the ENS but not in the vagus or sacral neural structures indicating the selectivity of these two antibodies. In the colonic myenteric plexus, dense hpChAT-ir neurons and fibers and varicose cChAT-ir fibers surrounding hpChAT-ir neurons were simultaneously visualized in 3D. The density of cChAT-ir varicose fibers in the outer submucosal plexus of both males and females were higher in the transverse and distal colon than in the proximal colon and in the myenteric plexus compared to the outer submucosal plexus and there was no cChAT innervation in the inner submucosal plexus. The density of hpChAT in the ENS showed no segmental or plexus differences in both sexes. Loperamide at the highest dose significantly decreased the density hpChAT-ir fibers + somata in the myenteric plexus of the distal colon. Discussion: These data showed the distinct density of central cholinergic innervation between myenteric and submucosal plexuses among colonic segments and the localization of cChAT-ir fibers around peripheral hpChAT neurons in 3D. The reduction of cholinergic myenteric innervation by chronic opiate treatment points to target altered prokinetic cholinergic pathway to counteract opiate constipation.

neurosciences
[Effect of Morphine Chloride on Contractility of Small Intestinal Muscle in Vitro or in Vivo and Its Mechanisms].

Zhi-Ying Feng,Lian-Gen Mao,Yuan Lu

DOI: https://doi.org/10.3785/j.issn.1008-9292.2008.03.010

2008-01-01

Abstract:OBJECTIVE:To investigate the effect of morphine chloride on small intestinal muscle in vitro or in vivo and its mechanisms.METHODS:Contractile amplitude, tension and frequency of the isolated small intestine of rabbits were measured before and after treatment of morphine chloride. The propulsive distance of magenta in intestinal tract was measured when different concentration of morphine chloride was given orally in mice.RESULT:After treatment of different concentration of morphine chloride (5 mg/L, 10 mg/L, 30 mg/L), the contractile activities of isolated small intestines of rabbits decreased significantly. The inhibitory effect of morphine chloride was blocked by naloxone, atropine, but potentiated by regitine. The propulsive distance of magenta in intestinal tract of intact mouse decreased after treatment with morphine chloride of various concentration (75, 150, 300 mg/L).CONCLUSION:Morphine chloride has an inhibitory effect on the contractility of rabbit small intestine in vitro or in vivo. Opioid receptor, choline and adrenal receptor might be involved in this effect.
Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine

J S Heyman,C L Williams,T F Burks,H I Mosberg,F Porreca

Abstract:The effect of pretreatment with naloxonazine on opioid-mediated antinociception against a thermal stimulus (55 degrees C warm-water tail-flick test) and inhibition of gastrointestinal transit at supraspinal and spinal levels was studied in unanesthetized mice. The mu-selective agonist [D-Ala2, N-methyl-Phe4, Gly5-ol]enkephalin (DAGO), the delta-selective agonist [D-Pen2, D-Pen5]enkephalin (DPDPE) and the reference mu-acting agonist morphine, all produced antinociception after either i.c.v. or intrathecal(ly) (i.t.) administration. Morphine and DAGO, but not DPDPE, inhibited gastrointestinal transit after i.c.v. administration, whereas all three agonists slowed gut propulsion when given i.t. A single s.c. naloxonazine pretreatment, 35 mg/kg given 24 hr earlier, failed to displace the dose-response line for i.c.v. DPDPE antinociception but produced a marked rightward displacement of the i.c.v. morphine and DAGO dose-response lines for antinociception. In contrast, naloxonazine (35 mg/kg) pretreatment did not alter the antinociceptive effects of i.t. morphine, DAGO or DPDPE. The effects of naloxonazine pretreatment on inhibition of gut propulsion were the converse of those observed for antinociception at supraspinal and spinal sites; naloxonazine had no effect on the antitransit properties of i.c.v. morphine and DAGO but inhibited the antitransit properties of all three agonists when they were given i.t. These results support the view that opioids may produce their supraspinal antitransit effects at a receptor different from that mediating antinociception; morphine and DAGO mediate their antitransit effects at a naloxonazine-insensitive site, whereas their antinociceptive effects are produced at the naloxonazine-sensitive receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
Sacral nerve stimulation with appropriate parameters improves constipation in rats by enhancing colon motility mediated via the autonomic-cholinergic mechanisms.

Zhihui Huang,Shiying Li,Robert D Foreman,Jieyun Yin,Ning Dai,Jiande Dz Chen

DOI: https://doi.org/10.1152/ajpgi.00150.2018

2019-01-01

Abstract:Although sacral nerve stimulation (SNS) has been applied for treating constipation. its parameters were adopted from SNS for fecal incontinence, its effects are limited, and mechanisms are largely unknown. We investigated the effects and mechanism of SNS with appropriate parameters on constipation in rats treated with loperamide. First, using rectal compliance as an outcome measure, an experiment was performed to derive effective SNS parameters. Then, a 7-day SNS was performed in rats with constipation induced by loperamide. Autonomic functions were assessed by spectral analysis of heart rate variability (HRV) derived from an electrocardiogram. Serum levels of pancreatic polypeptide (PP), norepinephrine (NE), and acetylcholine (ACh) in colon were assessed. 1) Acute SNS at 5 Hz, 100 p..s was found effective in enhancing rectal compliance and accelerating distal colon transit (P < 0.05 vs. sham SNS). 2) The 7-day SNS normalized loperamide-induced constipation, assessed by the number, weight, and water content of fecal pellets, and accelerated the distal colon transit (29.4 +/- 3.7 min with sham SNS vs. 16.4 +/- 5.3 min with SNS but not gastric emptying or intestinal transit. 3) SNS significantly increased vagal activity (P = 0.035) and decreased sympathetic activity (P = 0.012), assessed by spectral analysis of HRV as well as by the serum PP. 4) SNS increased ACh in the colon tissue; atropine blocked the accelerative effect of SNS on distal colon transit. We concluded that SNS with appropriate parameters improves constipation induced by loperamide by accelerating distal colon motility, mediated via the autonomic-cholinergic function. NEW & NOTEWORTHY Although sacral nerve stimulation (SNS) has been applied for treating constipation, its parameters were adopted from SNS for fecal incontinence, effects are limited, and mechanisms are largely unknown. This paper shows that SNS with appropriate parameters improves constipation induced by loperamide by accelerating distal colon motility mediated via the autonomic-cholinergic function.
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Yan Zhang,Dwight A Williams,Saheem A Zaidi,Yunyun Yuan,Amanda Braithwaite,Edward J Bilsky,William L Dewey,Hamid I Akbarali,John M Streicher,Dana E Selley

DOI: https://doi.org/10.1021/acschemneuro.5b00245

2016-01-01

ACS Chemical Neuroscience

Abstract:Mounting evidence has suggested that G protein-coupled receptors can be stabilized in multiple conformations in response to distinct ligands, which exert discrete functions through selective activation of various downstream signaling events. In accordance with this concept, we report biased signaling of one C6-heterocyclic substituted naltrexamine derivative, namely, 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) at the mu opioid receptor (MOR). NAP acted as a low efficacy MOR partial agonist in the G protein-mediated [(35)S]GTPγS binding assay, whereas it did not significantly induce calcium flux or β-arrestin2 recruitment. In contrast, it potently blocked MOR full agonist-induced β-arrestin2 recruitment and translocation. Additionally, NAP dose-dependently antagonized MOR full agonist-induced intracellular calcium flux and β-arrestin2 recruitment. Further results in an isolated organ bath preparation confirmed that NAP reversed the morphine-induced reduction in colon motility. Ligand docking and dynamics simulation studies of NAP at the MOR provided more supporting evidence for biased signaling of NAP at an atomic level. Due to the fact that NAP is MOR selective and preferentially distributed peripherally upon systemic administration while β-arrestin2 is reportedly required for impairment of intestinal motility by morphine, biased antagonism of β-arrestin2 recruitment by NAP further supports its utility as a treatment for opioid-induced constipation.
Regarding "Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms".

K. Ouriel

DOI: https://doi.org/10.1016/S0741-5214(99)70117-5

IF: 4.86

1999-10-01

Journal of Vascular Surgery

Abstract:
Regional differences of extrinsic and intrinsic cholinergic innervation and alterations by chronic opioid-induced constipation in the porcine colonic enteric nerve system

Pu-Qing Yuan,Tao Li,Million Mulugeta,Muriel Larauche,Jean-Pierre Bellier,Yvette Tache

DOI: https://doi.org/10.1152/physiol.2023.38.s1.5727607

IF: 11.8461

2023-05-01

Physiology

Abstract:The colon is richly innervated by extrinsic (ext) and intrinsic (int) cholinergic nerves from central and enteric nervous system (CNS and ENS) modulating colonic motility, secretion and inflammation. However, a challenge lies in our inability to anatomically distinguish such innervation in the colon. The porcine colon is regarded as a useful translational research model due to many similarities with human. The present study developed an approach to differentiate ext- and int-cholinergic innervation of the porcine colon using double immunolabeling with a novel mouse antibody against human peripheral choline acetyltransferase (hpChAT) combined with a rabbit antibody anti-common ChAT (cChAT) respectively. The spatial configuration of ext- and int- cholinergic innervation in the ENS was assessed on 3D images generated from CLARITY-cleared porcine colonic samples. Their densities were computationally quantitated using Imaris 9 within the inner and outer submucosal and myenteric plexuses (ISP, OSP, MP) along the proximal, transverse and distal colonic regions (pC, tC, dC) collected from 18 adult Yucatan minipigs including 6 naïve (3 of each sex), 4 vehicle controls (2 of each sex), 8 treated with loperamide, a μ opioid receptor agonist (LOP, 0.4 or 3 mg/kg/day, po, 4 weeks, 4/group, 2 of each sex). The specificities of cChAT and hpChAT antibodies were confirmed with porcine cervical vagal trunk (CVT), sacral spinal cord (SSC, S2-S4) and colonic ENS. The double labeling showed the strong cChAT immunoreactive (+) fibers in the CVT and neuronal somata and fibers in the SSC, but no hpChAT+ labeling was visualized in these structures. In the colonic MP, the dense hpChAT+ neurons and fibers and varicose cChAT+ fibers were simultaneously visualized. 3D images demonstrated that int- cholinergic neurons (hpChAT+) were closely surrounded by ext- cholinergic varicose fibers and dot like structures (cChAT+), presumably nerve terminals. The density of cChAT+ but not hpChAT+ fibers+somata showed significant differences among three segments (dC>tC>pC) within three enteric plexuses (MP>OSP>ISP) in naïve pigs. Compared to control groups, the high dose LOP induced a 1.3-fold decrease of cChAT+ fiber density in males (p<0.05) and 1.5-fold in females (p<0.05), and 2.2-fold decrease of hpChAT+ fibers+somata density in males (p<0.05) and 3.6-fold in female (p<0.01) with a 1.5-fold greater decrease in females than males (p<0.05) in the MP of the dC. This study demonstrates for the first time the ext- and int- cholinergic innervation, the spatial configuration in 3D structure, regional variations in the porcine colonic ENS and the reduction by chronic opiate use with greater in females than males. These findings provide neuroanatomical evidence of CNS-gut cross-talk via cholinergic innervation of the colon and point to the neuromodulation of this pathway to alleviate functional colonic disorders like chronic opioid-induced constipation. Supported by NIH/SPARC OT2OD024899. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

physiology
The P2Y1 receptor in the colonic myenteric plexus of rats and its correlation with opioid-induced constipation

Yuqiong Zhao,Huijuan Luo,Xiaojie Ren,Binghan Jia,Jinzhao Li,Lixin Wang,Junping Li

DOI: https://doi.org/10.1186/s12876-024-03119-9

2024-01-10

BMC Gastroenterology

Abstract:This study was designed to explore the expression changes of P2Y 1 receptors in the distal colonic myenteric layer of rats. An opioid induced constipation(OIC) rat model was generated by intraperitoneal (i.p) injection of loperamide. At 7 days post-treatment, the model rats were assessed by calculating the fecal water content and the gastrointestinal transit ratio. The immunofluorescence (IF)-based histochemical study was used to observe the distribution of P2Y 1 receptors in the distal colonic myenteric plexus. Western blotting (WB) was performed to evaluate the expression changes of P2Y 1 proteins in the myenteric layer, and the electrophysiological approaches were carried out to determine the regulatory roles of P2Y 1 receptors on distal colonic motor function. IF showed that P2Y 1 receptors are co-expressed MOR in the enteric nerve cells of the distal colonic myenteric plexus. Moreover, the WB revealed that the protein levels of P2Y 1 were significantly decreased in the distal colonic myenteric layer of OIC rats. In vitro tension experiments exhibited that the P2Y 1 receptor antagonist MRS2500 enhanced the spontaneous contraction amplitude, adding EM2 and β-FNA did not have any effect on MRS2500. Therefore, P2Y 1 receptor expression could be associated with the occurrence of OIC in this rat model and the regulation of colonic motility by MOR may be related to the release of purine neurotransmitters such as ATP in the colonic nervous system.

gastroenterology & hepatology
μ-Opioid Receptor–Mediated Enteric Glial Activation Is Involved in Morphine-Induced Constipation

Hui Gao,Yuxin Zhang,Yansong Li,Haiqing Chang,Bo Cheng,Na Li,Wei Yuan,Shuang Li,Qiang Wang

DOI: https://doi.org/10.1007/s12035-021-02286-0

IF: 5.682

2021-02-23

Molecular Neurobiology

Abstract:Among all the side effects, opioid-induced constipation (OIC) has the highest incidence rate in people who take chronic opioid therapy. Increasing evidence shows that enteric glial cells (EGCs) play a pivotal role in the modulation of gastrointestinal motility. We aim to investigate whether EGCs are involved in OIC and possible mechanisms. Eight-week male C57BL/6 mice were randomized into four groups: the control group, the morphine group, the gliotoxin fluorocitrate (FC) group, and the FC plus morphine group. OIC was induced by injection of morphine subcutaneously. Colonic motility was evaluated by in vivo motility assays and colonic migrating motor complex (CMMC) in vitro. Both the Ca2+ responses and the release of inflammatory cytokine by EGCs were detected in vitro. Proteins were detected by immunofluorescence staining and Western blot. The morphine group showed prolonged gastrointestinal motility compared with the control group. Once EGCs were disrupted by FC, such inhibitory effect was abolished. There was a remarkable enhancement of the GFAP expression on colonic EGCs. Immunofluorescence exhibited that μ-opioid receptor (MOR) collocated with GFAP, indicating the existence of MOR in EGCs. Moreover, morphine activated the EGCs significantly through enhancing GFAP expression and Ca2+ amplitude. Both effects can be reversed by MOR-siRNA. Morphine treatment elevated the enteric glial release of proinflammatory cytokines notably and this effect was abolished when EGCs were silenced by MOR-siRNA. The activation of EGCs via MOR and the increased proinflammatory cytokine from EGCs may be involved in morphine-induced constipation. These results provided a potential therapeutic target for OIC.

neurosciences
Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Essie Komla,David L. Stevens,Yi Zheng,Yan Zhang,William L. Dewey,Hamid Akbarali

DOI: https://doi.org/10.1124/jpet.119.256941

2019-01-01

Abstract:Opioids are highly effective analgesics, however, their therapeutic use is limited by adverse effects that include respiratory depression, dependence, and tolerance. Inflammation has been implicated as a significant driver for the development of tolerance to opioids. Recent studies show that chronic morphine in mice results in gut microbial dysbiosis and inflammation in the colon. In the present study, we examined whether colonic inflammation results in tolerance to the antinociceptive effects of morphine. Colonic inflammation was induced in mice by intrarectal administration of 2,4,6-trinitro-benzene sulfonic acid. The development of antinociceptive tolerance was determined by warm-water tail-immersion assay in mice implanted with 25-, 50-, or 75-mg morphine pellet. Colonic inflammation significantly enhanced the rate at which tolerance developed in each cohort of chronic morphine-treated mice. At the lowest dose of morphine pellet (25 mg), antinociceptive tolerance only developed in the presence of colonic inflammation, whereas in 50- and 75-mg pelleted mice, tolerance developed faster in the inflamed animals than in the noninflamed mice. The enhanced antinociceptive tolerance was attenuated with daily administration of peripheral opioid receptor antagonist, 6 beta-N-heterocyclic-substituted naltrexamine derivative 17-cyclopropyInnethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 beta-[(4'pyridyl) acetamido]nnorphinan (NAP)], irrespective of colonic inflammation. Collectively, these findings show that the rate of tolerance to morphine antinociception is exaggerated in the presence of colonic inflammation, and tolerance is prevented by a peripheral mu-opioid receptor antagonist. These studies suggest a peripheral component to the development of antinociceptive tolerance to opioids. Furthermore, peripherally selective opioid antagonists may be useful adjuncts in opioid-based pain management. SIGNIFICANCE STATEMENT This study supports the notion that inflammation influences the development of antinociceptive tolerance to chronic morphine exposure. We found that, in the presence of colonic inflammation, the rate of development of tolerance to the antinociceptive effects of morphine increased. We also found that treatment with a peripheral opioid receptor antagonist prevented morphine antinociceptive tolerance. Increasing opioid intake during an inflammatory state would result in decreased analgesia and enhanced analgesic tolerance, which puts patients with inflammatory bowel diseases, inflammatory joint diseases, and sickle cell anemia at risk for heavy opioid use.
Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Yunyun Yuan,Orgil Elbegdorj,Jianyang Chen,Shashidhar K. Akubathini,Feng Zhang,David L. Stevens,Irina O. Beletskaya,Krista L. Scoggins,Zhenxian Zhang,Phillip M. Gerk,Dana E. Selley,Hamid I. Akbarali,William L. Dewey,Yan Zhang

DOI: https://doi.org/10.1021/jm301247n

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:Peripheral selective μ opioid receptor (MOR) antagonists could alleviate the symptoms of opioid-induced constipation (OIC) without compromising the analgesic effect of opioids. However, a variety of adverse effects were associated with them, partially due to their relatively low MOR selectivity. NAP, a 6β-N-4'-pyridyl substituted naltrexamine derivative, was identified previously as a potent and highly selective MOR antagonist mainly acting within the peripheral nervous system. The noticeable diarrhea associated with it prompted the design and synthesis of its analogues in order to study its structure-activity relationship. Among them, compound 8 showed improved pharmacological profiles compared to the original lead, acting mainly at peripheral while increasing the intestinal motility in morphine-pelleted mice (ED(50) = 0.03 mg/kg). The slight decrease of the ED(50) compared to the original lead was well compensated by the unobserved adverse effect. Hence, this compound seems to be a more promising lead to develop novel therapeutic agents toward OIC.
Opioids and the Gastrointestinal Tract: The Role of Peripherally Active μ-Opioid Receptor Antagonists in Modulating Intestinal Permeability

Brian E. Lacy,David J. Cangemi

DOI: https://doi.org/10.14309/ajg.0000000000002887

2024-06-15

The American Journal of Gastroenterology

Abstract:Opioid receptors are found throughout the gastrointestinal tract, including the large intestine. Many patients treated with opioids experience opioid-induced constipation. Laxatives are not effective in most patients, and in those who do initially respond, the efficacy of laxatives generally diminishes over time. Additionally, opioid-induced constipation does not spontaneously resolve for most patients. However, complications of opioids extend far beyond simply slowing gastrointestinal transit. Opioid use can affect intestinal permeability through a variety of mechanisms. Toll-like receptors (TLRs) are a crucial component of innate immunity and are tightly regulated within the gut epithelium. Pathologic μ-opioid receptor and TLR signaling, resulting from chronic opioid exposure, disrupts intestinal permeability leading to potentially harmful bacterial translocation, elevated levels of bacterial toxins, immune activation, and increased cytokine production. Peripherally active μ-opioid receptor antagonists, including methylnaltrexone, are effective at treating opioid-induced constipation. Benefits extend beyond simply blocking the μ-opioid receptor; these agents also act to ameliorate opioid-induced disrupted intestinal permeability. In this review we briefly describe the physiology of the gastrointestinal epithelial border and discuss the impact of opioids on gastrointestinal function. Finally, we consider the use of peripherally active μ-opioid receptor antagonists to treat disrupted intestinal permeability resulting from opioid use and discuss the potential for improved morbidity and mortality in patients treated with methylnaltrexone for opioid-induced bowel disorders.

gastroenterology & hepatology
A54 DELTA OPIOID RECEPTOR SIGNALING MEDIATES OPIOID INDUCED TOLERANCE AND HYPERALGESIA IN COLONIC SENSORY NERVES

J O Jaramillo Polanco,C D Lopez Lopez,Y Yu,D E Reed,A E Lomax,S Vanner

DOI: https://doi.org/10.1093/jcag/gwz047.053

2020-02-01

Journal of the Canadian Association of Gastroenterology

Abstract:Abstract Background While opioid drugs are widely used for treating abdominal pain, prolonged exposure to opioids can induce tolerance and paradoxically increase pain. We previously showed in colonic afferent nerves that chronic morphine treatment causes tolerance and paradoxical hyperalgesia, however the mechanisms are unknown. Aims To evaluate the role of delta opioid receptor (DOR) signaling in opioid induced tolerance and hyperalgesia in colonic nerves during chronic morphine exposure. Methods C57BL/6 mice were injected (i.p.) twice daily for 7 days with escalating doses of morphine (10, 20, 30 mg/kg for the first 3 days, then 40mg/kg on 4th to 7th day); a subset of mice were also injected with 2.5 mg/kg naltrindole (NTI), a DOR antagonist. The analgesic response in vivo was monitored daily using the tail-flick test. To assess the effect of chronic morphine exposure, mice were euthanized on day 8, and the dorsal root ganglia (DRGs) and colons were harvested. Isolated DRG neurons were incubated with 1μM morphine (30 min) and neuronal excitability was determined by measuring the rheobase (amount of current required to elicit an action potential) using perforated patch clamp. To assess changes in colonic afferent nerve excitability, ex vivo afferent nerve recordings were obtained from flat-sheet colon preparations to determine the effects of 1μM morphine (10 min perfusion) on mechanosensitivity by probing with 1g von Frey hair. Results The tail flick test showed that the DOR antagonist NTI inhibited (30%) the maximal antinociceptive effect of morphine and reduced morphine tolerance. In patch clamp recordings, 1μM morphine paradoxically increased the excitability of small DRG neurons from morphine mice (rheobase decreased 28%; p<0.05, 2-way ANOVA), whereas this excitatory effect was absent on neurons from NTI+morphine mice. Acute application of 1μM morphine had no effect on afferent nerve responses to probing in morphine mice (14.9 vs 16.7 Hz; p=ns, paired t test, n=15) whereas it inhibited the afferent nerve response to probing in NTI+morphine mice (15.2 vs 9.9 Hz; p<0.001, paired t test, n=16). Furthermore, most single units from morphine mice had an increased response to probing following acute morphine application (7/15 vs 2/16 units excited), whereas most units form NTI-morphine mice were inhibited (14/16 vs. 3/15 units inhibited, P<0.001, Chi-square). Conclusions These findings suggest that DOR signaling plays a significant role in the development of opioid tolerance and hyperalgesia in colonic afferent nerves induced by chronic morphine treatment. Thus, antagonists of DOR may help to mitigate these side effects induced by opioids. Funding Agencies CCC
Cross‐reacting allergens in natural rubber latex and jelutong

K. Wrangsjö,M. Lundberg,B. Meding,M. Åhman,A. Karlberg,M. van Hage-Hamsten

DOI: https://doi.org/10.1034/j.1398-9995.1999.00369.x

1999-12-01

Abstract:tests with common inhalation allergens were positive for grass pollens (++). A prick-to-prick test with powder of red yeast rice dissolved in water (Food Line GmbH, Offenbach, Germany) was strongly positive (++++). The skin prick test, as well as speci®c IgE antibodies, was negative to rice. A subsequent prick-to-prick test with Monascus purpureus cultivated on agar (Department of Food Technology, University of Bonn, Germany) gave a similar, strongly positive result (++++), whereas 10 healthy controls remained negative. The cellular antigen stimulation test (CAST) was positive to red yeast rice and M. purpureus in different concentrations. Additionally, a disk was prepared with M. purpureus solution to detect serum IgE antibodies to M. purpureus by the radioallergosorbent test (RAST). Serologic analysis revealed speci®c IgE to M. purpureus (class 2 positive, 1.10 Allergopharma units, Allergopharma, Reinbek, Germany). Red yeast rice is produced by solid-state fermentation of washed and cooked nonglutinous rice by the fungus, M. purpureus, an ascomycete, which is red in color. Red yeast rice is a traditional East Asian product that has been used in China since the Tang Dynasty. It is called ``ang-kak'' or ``koji'' in Japan. Health-promoting effects are ascribed traditionally to the product, which is mostly sold as a powder. However, red yeast rice is mainly used as a food additive, particularly in meat as a preservative and condiment. It was shown in animal and human studies that M. purpureus extracts effectively lower serum lipid levels due to microbial metabolites such as monacolin K (mevinolin) with 3-hydroxy-3methylglutaryl conzyme A reductase inhibitor activity (2±4). Additionally, the observed bacteriostatic effects (5) have led to the use of M. purpureus fermentate as at least a partial substitute for nitrite in meat preservation. There is considerable global interest in the development of natural food additives that provide health bene®ts. However, possible adverse effects have to be considered. Our case highlights the importance of a detailed allergologic assessment of natural allergens by in vivo and, if available, by in vitro tests. To our knowledge, this is the ®rst documented case of anaphylaxis to red yeast rice due to immediate-type sensitivity to M. purpureus in which speci®c IgE antibodies could be shown.
Prevention of Loperamide-Induced Constipation in Mice and Alteration of 5-Hydroxytryotamine Signaling by <i>Ligilactobacillus salivarius</i> Li01

Bo Qiu,Lian Zhu,Shuobo Zhang,Shengyi Han,Yiqiu Fei,Furong Ba,Bjorn Berglund,Lanjuan Li,Mingfei Yao

DOI: https://doi.org/10.3390/nu14194083

IF: 5.9

2022-01-01

Nutrients

Abstract:Although Ligilactobacillus salivarius Li01 (Li01) has shown much promise in preventing multiple gastrointestinal diseases, the potential of the probiotic in alleviating constipation and the related mechanisms remain unclear. In this study, the effects of Li01 were evaluated in a loperamide-induced constipation mouse model. The results demonstrated that Li01 intervention can relieve constipation symptoms by improving water content, quantity, and morphology of feces and act as an intestinal barrier structure protector. Furthermore, Li01 can modulate gut motility (gastrointestinal transit rate), the fluid transit-associated expression of aquaporins, and the serum parameters vasoactive intestinal peptide, substance P, and somatostatin. Constipation significantly increased the levels of 5-hydroxytryotamine (5-HT) in serum (p < 0.01) and decreased the levels in the intestine (p < 0.001). Due to its function of elevating the expression of tryptophan hydroxylase 1, this was reversed after Li01 treatment. Li01 also promoted the expression of 5-HT receptor 3 and 4, indicating that the 5-HT signaling pathway may play a critical role in the mechanism by which Li01 alleviate constipation symptoms. Additionally, Li01 significantly altered the gut microbiota composition by enhancing the ratio of Firmicutes/Bacteroidetes and increasing the abundance of Rikenellaceae_RC9 genera. Based on the above results, Li01 may have the potential to effectively alleviate constipation by regulating the 5-HT pathway and alteration of the gut microbiota.
Coexpressed {delta}-, {mu}-, and {kappa}-Opioid Receptors Modulate Voltage-Gated Ca2+ Channels in Gastric-Projecting Vagal Afferent Neurons

Hannah J. Goudsward,Victor Ruiz-Velasco,Salvatore L. Stella,Lisa B. Willing,Gregory M. Holmes

DOI: https://doi.org/10.1124/molpharm.123.000774

2024-02-16

Molecular Pharmacology

Abstract:Opioid analgesics are frequently associated with gastrointestinal side effects, including constipation, nausea, dysphagia, and reduced gastric motility. Though it has been shown that stimulation of opioid receptors expressed in enteric motor neurons contributes to opioid-induced constipation, it remains unclear whether activation of opioid receptors in gastric-projecting nodose ganglia neurons contributes to the reduction in gastric motility and emptying associated with opioid use. In the present study, whole-cell patch-clamp recordings were performed to determine the mechanism underlying opioid receptor–mediated modulation of Ca 2+ currents in acutely isolated gastric vagal afferent neurons. Our results demonstrate that Ca V 2.2 channels provide the majority (71% ± 16%) of Ca 2+ currents in gastric vagal afferent neurons. Furthermore, we found that application of oxycodone, U-50488, or deltorphin II on gastric nodose ganglia neurons inhibited Ca 2+ currents through a voltage-dependent mechanism by coupling to the G α i/o family of heterotrimeric G-proteins. Because previous studies have demonstrated that the nodose ganglia expresses low levels of -opioid receptors, we also determined the deltorphin II concentration-response relationship and assessed deltorphin-mediated Ca 2+ current inhibition following exposure to the -opioid receptor antagonist ICI 174,864 (0.3 μM). The peak mean Ca 2+ current inhibition following deltorphin II application was 47% ± 24% (EC 50 = 302.6 nM), and exposure to ICI 174,864 blocked deltorphin II–mediated Ca 2+ current inhibition (4% ± 4% versus 37% ± 20%). Together, our results suggest that analgesics targeting any opioid receptor subtype can modulate gastric vagal circuits. SIGNIFICANCE STATEMENT This study demonstrated that in gastric nodose ganglia neurons, agonists targeting all three classical opioid receptor subtypes ( μ , , and ) inhibit voltage-gated Ca 2+ channels in a voltage-dependent mechanism by coupling to Gα i/o . These findings suggest that analgesics targeting any opioid receptor subtype would modulate gastric vagal circuits responsible for regulating gastric reflexes.

pharmacology & pharmacy
Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Ahmad A. Altarifi,Yunyun Yuan,Yan Zhang,Dana E. Selley,S. Stevens Negus

DOI: https://doi.org/10.1007/s00213-014-3719-7

2014-01-01

Psychopharmacology

Abstract:Rationale Low-efficacy mu opioid receptor agonists may be useful for some clinical indications, but clinically available low-efficacy mu agonists also have low selectivity for mu vs. kappa opioid receptors. NAQ (17-cyclopropylmethyl-3,14ß-dihydroxy-4,5α-epoxy-6α-[(3′-isoquinolyl)acetamido]morphinan) is a novel opioid receptor ligand with low-efficacy at mu receptors and greater mu-receptor selectivity than existing low-efficacy agonists. Objectives This study examined behavioral effects of NAQ in rats using an intracranial self-stimulation (ICSS) procedure that has been used previously to examine other opioids. NAQ effects were examined before, during, and after chronic morphine treatment, and effects of NAQ were compared to effects of nalbuphine and naltrexone. Methods Adult male Sprague–Dawley rats were trained to respond for electrical brain stimulation delivered via electrodes implanted in the medial forebrain bundle. A range of brain stimulation frequencies maintained a wide range of baseline ICSS rates. Effects of NAQ (0.32–10 mg/kg), nalbuphine (1.0 mg/kg), and naltrexone (0.1 mg/kg) were determined before morphine treatment and during treatment with 3.2 and 18 mg/kg/day morphine. NAQ effects were also redetermined beginning 2 weeks after termination of morphine treatment. Results NAQ produced weak ICSS facilitation in morphine-naïve rats but more robust ICSS facilitation during and after morphine treatment and also reversed morphine withdrawal-associated depression of ICSS. These effects were similar to effects of nalbuphine. Conclusions These results agree with the in vitro characterization of NAQ as a low-efficacy mu agonist. Opioid exposure may enhance abuse-related effects of NAQ, but NAQ may also serve as a low-efficacy and relatively safe option for treatment of opioid withdrawal or dependence.
6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Yunyun Yuan,David L Stevens,Amanda Braithwaite,Krista L Scoggins,Edward J Bilsky,Hamid I Akbarali,William L Dewey,Yan Zhang

DOI: https://doi.org/10.1016/j.bmcl.2012.05.075

IF: 2.94

2012-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A 6β-N-heterocyclic substituted naltrexamine derivative, NAP, was proposed as a peripheral mu opioid receptor (MOR) selective antagonist based on the in vitro and in vivo pharmacological and pharmacokinetic studies. To further validate this notion, several functional assays were carried out to fully characterize this compound. In the charcoal gavage and intestinal motility assay in morphine-pelleted mice, when administered 0.3mg/kg or higher doses up to 3mg/kg subcutaneously, NAP significantly increased the intestinal motility compared to the saline treatment. The comparative opioid withdrawal precipitation study and the lower locomotor assay demonstrated that NAP showed only marginal intrinsic effect in the central nervous system either given subcutaneously or intravenously: no jumps were witnessed for the tested animals even given up to a dose of 50mg/kg, while similar noticeable wet-dog shakes only occurred at the dose 50 times of those for naloxone or naltrexone, and significant reduction of the hyper-locomotion only happened at the dose as high as 32mg/kg. Collectively, these results suggested that NAP may serve as a novel lead to develop peripheral MOR selective antagonist which might possess therapeutic potential for opioid-induced bowel dysfunction (OBD), such as opioid-induced constipation (OIC).
Nanoconjugated NAP As a Potent and Periphery Selective Mu Opioid Receptor Modulator to Treat Opioid-Induced Constipation.

Guoyan G. Xu,Olga Yu. Zolotarskaya,Dwight A. Williams,Yunyun Yuan,Dana E. Selley,William L. Dewey,Hamid I. Akbarali,Hu Yang,Yan Zhang

DOI: https://doi.org/10.1021/acsmedchemlett.6b00382

2017-01-01

ACS Medicinal Chemistry Letters

Abstract:Opioids are the mainstay for cancer and noncancer pain management. However, their use is often associated with multiple adverse effects. Among them, the most common and persistent one is probably opioid-induced constipation (OIC). Periphery selective opioid antagonists may alleviate the symptoms of OIC without compromising the analgesic effects of opioids. Recently our laboratories have identified one novel lead compound, 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)acetamido]morphinan (NAP), as a peripherally selective mu opioid receptor ligand carrying subnanomolar affinity to the mu opioid receptor and over 100-folds of selectivity over both the delta and kappa opioid receptors, with reasonable oral availability and half-life, and potential to treat OIC. Nanoparticle-based drug delivery systems are now widely considered due to their technological advantages such as good stability, high carrier capacity, low therapeutic side effects, etc. Herein we report nanoparticle supported NAP as a potential candidate for OIC treatment with improved peripheral selectivity over the original lead compound NAP.
[Roles of Enteric Nervous System Neurotransmitters and Interstitial Cells of Cajal in the Colon in Slow Transit Constipation in Rats].

Yun-Guang Bao,Xiao-Li Shu,Xiao-Bing Li,Wei-Zhong Gu,Ai-Juan Ying,Chan Zhao,Bi-You Ou,Mi-Zu Jiang

2009-01-01

Abstract:OBJECTIVETo evaluate the roles of enteric nervous system neurotransmitters, nitric oxide (NO), substance P (SP) and vasoactive intestinal polypeptide (VIP), and interstitial cells of Cajal (ICC) in the colon in slow transit constipation in rats.METHODSThirty-two healthy Wistar rats were randomly assigned to control and constipated groups. In the constipated group, the rats were daily administered with diphenoxylate (8 mg/kg) to develop slow transit constipation, while the control rats were fed with water. The number and the weight of fecal granule and the body weight of rats were recorded every 5 days for 90 days. Transit functions of intestinal movement were examined by an activated charcoal suspension pushing test one week after stopping the administration of diphenoxylate. The levels of NO and SP in the colonic mucosa were measured by nitrate reductase methods and ELISA respectively. The distribution of VIP and ICC positive cells confirmed with symbolic c-kit+ cells in the colonic wall were observed by immunohistochemical methods.RESULTSThe daily number of fecal granule in the constipated group was significantly less than that in the control group (P<0.01). The mean weight of each fecal granule in the constipated group was significantly higher than that in the control group (P<0.01). The discharge time of the first granule of black faeces in the constipated group (430.2+/- 132.1 min) was significantly longer than that in the control group (337.2+/- 74.7 min; P<0.05). There were no significant differences in NO and SP levels and the density of VIP positive cells in the distal colonic segment between the two groups. The number of c-kit+ cells in the distal colonic wall in the constipated group was significantly reduced compared with that in the control group (P<0.05).CONCLUSIONSThe reduction of ICC number in the distal colon may be contributed to the pathogenesis of slow transit constipation in rats.

[ULTRASTRUCTURE OF PARACOCCIDIOIDES BRASILIENSIS IN CULTURES OF THE YEAST-LIKE PHASE].

New insight on the enteric cholinergic innervation of the pig colon by central and peripheral nervous systems: reduction by repeated loperamide administration

[Effect of Morphine Chloride on Contractility of Small Intestinal Muscle in Vitro or in Vivo and Its Mechanisms].

Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine

Sacral nerve stimulation with appropriate parameters improves constipation in rats by enhancing colon motility mediated via the autonomic-cholinergic mechanisms.

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Regarding "Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms".

Regional differences of extrinsic and intrinsic cholinergic innervation and alterations by chronic opioid-induced constipation in the porcine colonic enteric nerve system

The P2Y1 receptor in the colonic myenteric plexus of rats and its correlation with opioid-induced constipation

μ-Opioid Receptor–Mediated Enteric Glial Activation Is Involved in Morphine-Induced Constipation

Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Opioids and the Gastrointestinal Tract: The Role of Peripherally Active μ-Opioid Receptor Antagonists in Modulating Intestinal Permeability

A54 DELTA OPIOID RECEPTOR SIGNALING MEDIATES OPIOID INDUCED TOLERANCE AND HYPERALGESIA IN COLONIC SENSORY NERVES

Cross‐reacting allergens in natural rubber latex and jelutong

Prevention of Loperamide-Induced Constipation in Mice and Alteration of 5-Hydroxytryotamine Signaling by <i>Ligilactobacillus salivarius</i> Li01

Coexpressed {delta}-, {mu}-, and {kappa}-Opioid Receptors Modulate Voltage-Gated Ca2+ Channels in Gastric-Projecting Vagal Afferent Neurons

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Nanoconjugated NAP As a Potent and Periphery Selective Mu Opioid Receptor Modulator to Treat Opioid-Induced Constipation.

[Roles of Enteric Nervous System Neurotransmitters and Interstitial Cells of Cajal in the Colon in Slow Transit Constipation in Rats].